A
Agilent Technologies, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Strong buy
+62/100
Last price
169.33
▼ 1.70 (1.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
171.04
Day high
176.38
Day low
168.01
Volume
1.87M
Market cap
$47.75B
P/E (TTM)
33.40
52W range
108.35 – 177.05
Trailing performance
Returnvs SPY
1W
-3.26%
-5.2%
1M
+12.24%
+11.1%
3M
+31.19%
+26.7%
6M
+48.69%
+30.5%
YTD
+24.44%
+10.2%
1Y
+19.55%
+3.1%
3Y
+51.43%
-30.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on A open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+7.46K
Net buying
Buy transactions
2
9.69K shares
Sell transactions
2
2.23K shares
Net transactions
+4
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
538.48K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | BOEHNLEIN GLENN S Director |
STOCK | 817 | $119.98K | Direct |
| Sep 4, 26 | DOLSTEN MIKAEL Director |
SELL | 634 | $95.97K | Direct |
| May 29, 26 | DOLSTEN MIKAEL Director |
SELL | 1.60K | $216.67K | Direct |
| May 19, 26 | BUCKNER MICHAEL STEVEN Officer |
STOCK | 8.87K | $0 | Direct |
| Mar 19, 26 | BRAWLEY OTIS W Director |
STOCK | 3.05K | $340.39K | Direct |
| Mar 19, 26 | WILSON DOW R Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | BROWN JUDY LYNNE GAWLIK Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | SCANGOS GEORGE A Director |
STOCK | 3.21K | $359.28K | Direct |
| Mar 19, 26 | KOH BOON HWEE Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | ANAND MALA Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | RATAJ SUE H Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | DOLSTEN MIKAEL Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | PODOLSKY DANIEL K Director |
STOCK | 2.16K | $241.16K | Direct |
| Mar 19, 26 | SORIOT PASCAL Director |
STOCK | 2.16K | $241.16K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANCHER JENSEN HENRIK |
Officer | 90.67K | Stock Award(Grant) |
FIELDS-KUNZ HEIDI |
Director | — | Stock Award(Grant) |
GONSALVES RODNEY |
Officer | — | Stock Gift |
KOH BOON HWEE |
Director | 63.18K | Stock Award(Grant) |
MCDONNELL PADRAIG |
Chief Executive Officer | 69.03K | Stock Award(Grant) |
MCMAHON ROBERT W |
Chief Financial Officer | 172.19K | Stock Award(Grant) |
PODOLSKY DANIEL K |
Director | 38.18K | Stock Award(Grant) |
RATAJ SUE H |
Director | 23.62K | Stock Award(Grant) |
RIEMANN ANGELICA |
Officer | 29.56K | Stock Award(Grant) |
SCANGOS GEORGE A |
Director | 41.75K | Stock Award(Grant) |
Fundamentals
Market cap$47.75B
Enterprise value$50.13B
Revenue (TTM)$7.37B
Gross profit$3.96B
EBITDA$2.08B
Net income$1.44B
EPS (TTM)$5.07
Free cash flow$1.06B
Total cash$1.76B
Total debt$4.15B
Book value / share$26.11
Shares outstanding281.97M
Float280.96M
Short % of float2.05%
Dividend yield0.60%
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E33.40
Forward P/E25.06
PEG ratio1.41
Price / sales—
Price / book6.48
EV / revenue6.80
EV / EBITDA24.10
Gross margin53.65%
Operating margin25.56%
Profit margin19.53%
Return on equity20.97%
Return on assets8.63%
Debt / equity56.34
Current ratio2.05
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.95B | $6.51B | $6.83B | $6.85B | +6.7% |
| Operating revenue | $6.95B | $6.51B | $6.83B | $6.85B | +6.7% |
| Cost of revenue | $3.31B | $2.98B | $3.37B | $3.13B | +11.1% |
| Gross profit | $3.64B | $3.54B | $3.46B | $3.72B | +3.1% |
| Research & development | $455.00M | $479.00M | $481.00M | $467.00M | -5.0% |
| Selling, general & admin | $1.71B | $1.57B | $1.63B | $1.64B | +9.0% |
| Total operating expense | $2.16B | $2.05B | $2.12B | $2.10B | +5.7% |
| Operating income | $1.48B | $1.49B | $1.35B | $1.62B | -0.6% |
| Net interest income | -$50.00M | -$16.00M | -$44.00M | -$75.00M | -212.5% |
| Pre-tax income | $1.44B | $1.52B | $1.34B | $1.50B | -5.7% |
| Tax provision | $132.00M | $232.00M | $99.00M | $250.00M | -43.1% |
| Net income | $1.30B | $1.29B | $1.24B | $1.25B | +1.1% |
| Net income to common | $1.30B | $1.29B | $1.24B | $1.25B | +1.1% |
| Basic EPS | 4.59 | 4.44 | 4.22 | 4.19 | +3.4% |
| Diluted EPS | 4.57 | 4.43 | 4.19 | 4.18 | +3.2% |
| EBIT | $1.55B | $1.62B | $1.43B | $1.59B | -4.3% |
| EBITDA | $1.83B | $1.87B | $1.71B | $1.91B | -2.1% |
| Basic shares | 284.00M | 290.00M | 294.00M | 299.00M | -2.1% |
| Diluted shares | 285.00M | 291.00M | 296.00M | 300.00M | -2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.79B | $1.33B | $1.59B | $1.05B | +34.6% |
| Cash & short-term investments | $1.79B | $1.33B | $1.59B | $1.05B | +34.6% |
| Accounts receivable | $1.49B | $1.32B | $1.29B | $1.41B | +12.3% |
| Inventory | $1.02B | $972.00M | $1.03B | $1.04B | +5.5% |
| Total current assets | $4.59B | $3.96B | $4.19B | $3.78B | +16.0% |
| Property, plant & equipment | $2.02B | $1.78B | $1.27B | $1.10B | +13.8% |
| Goodwill & intangibles | $4.92B | $5.02B | $4.43B | $4.77B | -2.1% |
| Total assets | $12.73B | $11.85B | $10.76B | $10.53B | +7.4% |
| Total current liabilities | $2.35B | $1.90B | $1.60B | $1.86B | +23.9% |
| Current debt | $304.00M | $45.00M | — | $36.00M | +575.6% |
| Long-term debt | $3.05B | $3.35B | $2.73B | $2.73B | -8.8% |
| Total debt | $3.35B | $3.39B | $2.73B | $2.77B | -1.1% |
| Total liabilities | $5.99B | $5.95B | $4.92B | $5.23B | +0.6% |
| Retained earnings | $1.39B | $750.00M | $782.00M | $324.00M | +85.2% |
| Shareholder equity | $6.74B | $5.90B | $5.84B | $5.30B | +14.3% |
| Working capital | $2.25B | $2.06B | $2.58B | $1.92B | +8.9% |
| Net tangible assets | $1.82B | $874.00M | $1.41B | $532.00M | +108.6% |
| Shares issued | 283.05M | 285.19M | 292.12M | 295.00M | -0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.30B | $1.29B | $1.24B | $1.25B | +1.1% |
| Depreciation & amortisation | $288.00M | $257.00M | $271.00M | $317.00M | +12.1% |
| Stock-based compensation | $128.00M | $129.00M | $111.00M | $125.00M | -0.8% |
| Change in working capital | -$131.00M | $83.00M | -$116.00M | -$478.00M | -257.8% |
| Operating cash flow | $1.56B | $1.75B | $1.77B | $1.31B | -11.0% |
| Capital expenditure | -$407.00M | -$378.00M | -$298.00M | -$291.00M | -7.7% |
| Investing cash flow | -$394.00M | -$1.26B | -$310.00M | -$338.00M | +68.7% |
| Share buybacks | -$425.00M | -$1.15B | -$575.00M | -$1.14B | +63.0% |
| Dividends paid | -$282.00M | -$274.00M | -$265.00M | -$250.00M | -2.9% |
| Financing cash flow | -$715.00M | -$752.00M | -$930.00M | -$1.37B | +4.9% |
| Free cash flow | $1.15B | $1.37B | $1.47B | $1.02B | -16.1% |
| End cash position | $1.79B | $1.33B | $1.59B | $1.06B | +34.5% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.88B | $1.83B | $1.80B | $1.86B | $1.74B | +2.3% |
| Operating revenue | $1.88B | $1.83B | $1.80B | $1.86B | $1.74B | +2.3% |
| Cost of revenue | $836.00M | $845.00M | $852.00M | $871.00M | $850.00M | -1.1% |
| Gross profit | $1.04B | $990.00M | $946.00M | $990.00M | $888.00M | +5.3% |
| Research & development | $123.00M | $126.00M | $117.00M | $119.00M | $111.00M | -2.4% |
| Selling, general & admin | $475.00M | $465.00M | $476.00M | $428.00M | $417.00M | +2.2% |
| Total operating expense | $598.00M | $591.00M | $593.00M | $547.00M | $528.00M | +1.2% |
| Operating income | $444.00M | $399.00M | $353.00M | $443.00M | $360.00M | +11.3% |
| Net interest income | -$14.00M | -$12.00M | -$10.00M | -$10.00M | -$12.00M | -16.7% |
| Pre-tax income | $444.00M | $408.00M | $364.00M | $442.00M | $366.00M | +8.8% |
| Tax provision | $82.00M | $69.00M | $59.00M | $8.00M | $30.00M | +18.8% |
| Net income | $362.00M | $339.00M | $305.00M | $434.00M | $336.00M | +6.8% |
| Net income to common | $362.00M | $339.00M | $305.00M | $434.00M | $336.00M | +6.8% |
| Basic EPS | 1.28 | 1.20 | 1.08 | 1.53 | 1.18 | +6.7% |
| Diluted EPS | 1.28 | 1.20 | 1.07 | 1.53 | 1.18 | +6.7% |
| EBIT | $473.00M | $433.00M | $389.00M | $469.00M | $394.00M | +9.2% |
| EBITDA | $539.00M | $500.00M | $456.00M | $540.00M | $466.00M | +7.8% |
| Basic shares | 282.00M | 282.00M | 283.00M | 283.00M | 284.00M | 0.0% |
| Diluted shares | 283.00M | 283.00M | 284.00M | 284.00M | 285.00M | 0.0% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.76B | $1.81B | $1.76B | $1.79B | $1.53B | -2.7% |
| Cash & short-term investments | $1.76B | $1.81B | $1.76B | $1.79B | $1.53B | -2.7% |
| Accounts receivable | $1.48B | $1.50B | $1.52B | $1.49B | $1.09B | -1.3% |
| Inventory | $1.12B | $1.09B | $1.06B | $1.02B | $1.01B | +2.6% |
| Total current assets | $4.69B | $4.76B | $4.62B | $4.59B | $4.25B | -1.5% |
| Property, plant & equipment | $2.13B | $2.10B | $2.08B | $2.02B | $1.97B | +1.7% |
| Goodwill & intangibles | $5.94B | $4.89B | $4.91B | $4.92B | $4.94B | +21.4% |
| Total assets | $13.97B | $13.06B | $12.81B | $12.73B | $12.23B | +6.9% |
| Total current liabilities | $2.29B | $2.27B | $2.23B | $2.35B | $1.89B | +0.9% |
| Current debt | $304.00M | $304.00M | $304.00M | $304.00M | $59.00M | 0.0% |
| Long-term debt | $3.65B | $3.05B | $3.05B | $3.05B | $3.35B | +19.5% |
| Total debt | $3.95B | $3.35B | $3.35B | $3.35B | $3.41B | +17.7% |
| Total liabilities | $6.60B | $5.94B | $5.91B | $5.99B | $5.86B | +11.1% |
| Retained earnings | $1.91B | $1.69B | $1.48B | $1.39B | $1.10B | +13.0% |
| Shareholder equity | $7.36B | $7.12B | $6.91B | $6.74B | $6.37B | +3.4% |
| Working capital | $2.40B | $2.49B | $2.38B | $2.25B | $2.36B | -3.6% |
| Net tangible assets | $1.43B | $2.23B | $2.00B | $1.82B | $1.43B | -36.0% |
| Shares issued | 281.97M | 282.22M | 282.70M | 283.05M | 283.59M | -0.1% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $362.00M | $339.00M | $305.00M | $434.00M | $336.00M | +6.8% |
| Depreciation & amortisation | $66.00M | $67.00M | $67.00M | $71.00M | $72.00M | -1.5% |
| Stock-based compensation | $32.00M | $32.00M | $41.00M | $26.00M | $32.00M | 0.0% |
| Change in working capital | $18.00M | -$211.00M | -$180.00M | $85.00M | -$82.00M | +108.5% |
| Operating cash flow | $519.00M | $277.00M | $268.00M | $545.00M | $362.00M | +87.4% |
| Capital expenditure | -$80.00M | -$76.00M | -$93.00M | -$93.00M | -$103.00M | -5.3% |
| Investing cash flow | -$1.03B | -$77.00M | -$93.00M | -$90.00M | -$96.00M | -1,240.3% |
| Share buybacks | -$78.00M | -$65.00M | -$152.00M | -$85.00M | -$85.00M | -20.0% |
| Dividends paid | -$72.00M | -$72.00M | -$72.00M | -$70.00M | -$71.00M | 0.0% |
| Financing cash flow | $471.00M | -$144.00M | -$222.00M | -$200.00M | -$219.00M | +427.1% |
| Free cash flow | $439.00M | $201.00M | $175.00M | $452.00M | $259.00M | +118.4% |
| End cash position | $1.76B | $1.81B | $1.76B | $1.79B | $1.54B | -2.7% |
Options analytics
Put / call volume
0.44
Call-heavy session
Put / call open interest
1.33
Positioning, not flow
Max pain
160.00
-5.5% from spot
ATM implied vol
0.8%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
250
Contracts, this expiry
Put volume
111
Contracts, this expiry
Heaviest call OI
165.00
1.73K contracts
Heaviest put OI
140.00
4.14K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | 1.49 | 1.62 | +9.0% |
| Apr 2026 | 1.41 | 1.49 | +5.8% |
| Jan 2026 | 1.37 | 1.36 | -0.6% |
| Oct 2025 | 1.58 | 1.59 | +0.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.73 | 18 | $1.99B | +6.9% |
| Next quarter | 1.50 | 11 | $1.93B | +7.1% |
| Current year | 6.20 | 21 | $7.50B | +8.0% |
| Next year | 6.76 | 22 | $7.98B | +6.4% |
Analyst targets & ownership
Mean target$176.50
High target$195.00
Low target$155.00
Implied upside4.23%
Analyst count20
ConsensusBUY
Strong buy / Buy4 / 11
Hold7
Sell / Strong sell0 / 0
Held by insiders0.19%
Held by institutions95.42%
Institutions holding1.61K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
170.86
-0.89% from price
SMA 20
161.81
+4.65% from price
SMA 50
153.81
+10.09% from price
SMA 100
141.65
+19.55% from price
SMA 200
133.15
+27.17% from price
EMA 12
167.63
+1.01% from price
EMA 26
161.98
+4.54% from price
EMA 50
154.91
+9.31% from price
RSI (14)
61.3
Neutral
MACD (12,26,9)
5.65
Hist 0.09
ATR (14)
5.46
3.23% of price
Realised vol 30D
30.4%
Annualised
Bollinger upper
183.25
20, 2σ
Bollinger lower
140.36
20, 2σ
50 / 200 cross
Golden
153.81 vs 133.15
Trend bias
Above 200
+27.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.84
Less volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
30.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.9%
Peak to trough
Max drawdown 5Y
-39.6%
Peak to trough
ATR 14
5.46
3.23% of price
Beta (reported)
1.21
5Y monthly, from filing
Short interest
Shares short
5.08M
Prior 5.17M
Change vs prior
-1.8%
Shorts covering
% of float
2.05%
Normal
% of shares out
1.80%
Against total outstanding
Days to cover
2.1
Liquid
Float
280.96M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 28, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 27, 26 | Stifel | MAINTAINED | Buy | Buy |
| Aug 27, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Aug 27, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 27, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Bernstein | MAINTAINED | Outperform | Outperform |
| Aug 27, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 27, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 27, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate$1.02 / yr
Forward yield0.60%
5-year avg yield0.68%
Payout ratio19.98%
Ex-dividend dateOct 6, 2026
Next pay dateOct 28, 2026
Last split1398:1000
Split dateNov 3, 2014
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Offering Registrations
S-4 · 2026-09-01
Corporate Changes & Voting Matters
8-K · 2026-08-26
Corporate Changes & Voting Matters
8-K · 2026-06-25
Periodic Financial Reports
10-Q · 2026-06-01
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-04
Headlines
Barclays Adjusts Price Target on Agilent Technologies to $195 From $175, Keeps Overweight Rating
MT Newswires · 23h ago
Why Is Medtronic (MDT) Down 6.4% Since Last Earnings Report?
Zacks · 6d ago
Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
Business Wire · 6d ago
Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
Business Wire · 8d ago
3 Healthcare Stocks That Fall Short
StockStory · 9d ago
Agilent Technologies (A) Tests Valuation On Exchange Offer And Recurring Revenue Story
Simply Wall St. · 10d ago
Agilent (A) Up 9.6% Since Last Earnings Report: Can It Continue?
Zacks · 12d ago
If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
Zacks · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.